Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) – Investment analysts at Roth Capital increased their FY2016 EPS estimates for shares of Conatus Pharmaceuticals in a research note issued on Wednesday. Roth Capital analyst S. Yaniv now anticipates that the firm will post earnings per share of ($1.27) for the year, up from their previous forecast of ($1.38). Roth Capital also issued estimates for Conatus Pharmaceuticals’ Q4 2016 earnings at ($0.31) EPS, Q1 2017 earnings at ($0.26) EPS, Q2 2017 earnings at ($0.26) EPS, Q3 2017 earnings at ($0.26) EPS, Q4 2017 earnings at ($0.26) EPS, FY2017 earnings at ($1.08) EPS, FY2018 earnings at ($1.13) EPS, FY2019 earnings at ($1.24) EPS and FY2020 earnings at ($1.38) EPS.

Conatus Pharmaceuticals (NASDAQ:CNAT) last issued its quarterly earnings results on Tuesday, November 8th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.34) by $0.03. During the same period last year, the business earned ($0.31) earnings per share.

Earnings History and Estimates for Conatus Pharmaceuticals (NASDAQ:CNAT)

Several other research firms have also issued reports on CNAT. Stifel Nicolaus reduced their price target on Conatus Pharmaceuticals from $6.00 to $5.00 and set a “buy” rating on the stock in a research report on Wednesday, November 9th. Zacks Investment Research lowered Conatus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Monday. Brean Capital set a $7.00 price target on Conatus Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 5th. JMP Securities restated a “buy” rating on shares of Conatus Pharmaceuticals in a research report on Wednesday, November 9th. Finally, FBR & Co restated an “outperform” rating and set a $16.00 price target on shares of Conatus Pharmaceuticals in a research report on Tuesday, August 30th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $8.54.

Conatus Pharmaceuticals (NASDAQ:CNAT) opened at 2.09 on Monday. The firm’s market capitalization is $46.13 million. The firm has a 50-day moving average price of $1.89 and a 200 day moving average price of $2.06. Conatus Pharmaceuticals has a 52 week low of $1.40 and a 52 week high of $4.05.

Large investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp boosted its position in Conatus Pharmaceuticals by 2.0% in the second quarter. Bank of New York Mellon Corp now owns 86,296 shares of the biotechnology company’s stock worth $178,000 after buying an additional 1,668 shares during the last quarter. AXA boosted its position in Conatus Pharmaceuticals by 1.4% in the second quarter. AXA now owns 1,085,775 shares of the biotechnology company’s stock worth $2,237,000 after buying an additional 14,939 shares during the last quarter. Vanguard Group Inc. boosted its position in Conatus Pharmaceuticals by 3.5% in the second quarter. Vanguard Group Inc. now owns 448,938 shares of the biotechnology company’s stock worth $925,000 after buying an additional 15,300 shares during the last quarter. D. E. Shaw & Co. Inc. boosted its position in Conatus Pharmaceuticals by 94.5% in the third quarter. D. E. Shaw & Co. Inc. now owns 87,788 shares of the biotechnology company’s stock worth $175,000 after buying an additional 42,649 shares during the last quarter. Finally, KCG Holdings Inc. purchased a new position in Conatus Pharmaceuticals during the third quarter worth approximately $135,000. Institutional investors and hedge funds own 22.89% of the company’s stock.

About Conatus Pharmaceuticals

Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.

5 Day Chart for NASDAQ:CNAT

Receive News & Stock Ratings for Conatus Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.